Celon Pharma
Manufacturing · Poland · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Ogrodowa 2a, Lomianki, Masovian Voivodes...Phone Number
+48 227515933Website
www.celonpharma.comRevenue
$23.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Celon Pharma
Celon Pharma S.A. is an integrated pharmaceutical company engaged in advanced scientific research and the production of modern medications. The company also effectively markets its own products, which help thousands of patients maintain better and longer lives. Celon Pharma focuses on research and development, offering generic products to its clients. Its commitment to innovation and patient care positions it as a key player in the pharmaceutical industry.Explore more
Celon Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celon Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Celon Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Celon Pharma launches new products
Website visits: Recent activity has been detected on your website
Check out if Celon Pharma is spiking on competitors!
Click to see if Celon Pharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Celon Pharma has new funding data
Celon Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Celon Pharma
Earning: See what the market has to say on Celon Pharma recently announced quarterly report
Recommended Actions
Find VP level buyers at Celon Pharma
Find 2 more new buyers
Company Profile Activity
Activity Insights
Celon Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Celon Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Celon Pharma.
Celon Pharma Tech Stack
A closer look at the technologies used by Celon Pharma
Most Recent Scoops
Hiring Plans
Celon Pharma has more open roles in Operations than it has had at any time in the past 12 months.
Hiring Plans
Hiring Plans
Celon Pharma is hiring in Medical & Health for the first time in 12 months.
Hiring Plans
Person-Based
Person-Based
Person-Based
Celon Pharma News & Media
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease
WARSAW, Poland, March 04, 2025 (GLOBE NEWSWIRE) -- Celon Pharma S.A. (CLN.WA) today announces robust and positive Phase 2 clinical trial results for its PDE10A inhibitor (CPL’36), a novel, oral, once-daily medication for the treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson’s disease. The study met its primary endpoint and many of its secondary endpoints. CPL’36 demonstrated robust and consistent efficacy across all utilized scales measuring improvement in treatment of LID in ParkinsonStrong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsychotic
-Statistically significant benefit demonstrated in primary endpoint of positive subscale of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) at Week 4-Celon Pharma Announces Results of Phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)
KIELPIN, Poland, June 17, 2024 (GLOBE NEWSWIRE) -- Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA). The primary endpoint results are statistically significant, the primary endpoint is met.Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus, Novartis, Relmada, Beckley Psytech, COMPASS, Axsome, Celon Pharma
The treatment-resistant depression market size in the 7MM is expected to increase by 2032. As per DelveInsight’s estimation, the treatment space will experience a significant impact in the coming years due to the improvement in the rise in the number of healthcare spending across the world, in the forecast period (2023‒2032). The treatment-resistant depression market size in the 7MM is expected to increase by 2032. As per DelveInsight’s estimation, the treatment space will experience a
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Celon Pharma
Sign Up For FreeTo access detailed company insights
Celon Pharma S.A. is an integrated pharmaceutical company engaged in advanced scientific research and the production of modern medications. The company also effectively markets its own products, which help thousands of patients maintain better and longer lives. Celon Pharma focuses on research and development, offering generic products to its clien... Read More
